HCC-话题@MedSci

#HCC#

114篇内容 | 5776人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259536, encodeId=81c51259536b3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, objectType=article, longId=214189, objectId=ceaa214189f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ceaa214189f7, replyNumber=0, likeNumber=71, createdTime=2021-07-15, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ceaa214189f7, moduleTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ceaa214189f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259535, encodeId=d1fc125953528, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=51, createdTime=2021-07-03, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259534, encodeId=22b61259534fc, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology:对于HCC的诊断，不要只看动脉期！, objectType=article, longId=212732, objectId=4162212e3259, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4162212e3259, replyNumber=0, likeNumber=84, createdTime=2021-06-16, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4162212e3259, moduleTitle=Radiology:对于HCC的诊断，不要只看动脉期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4162212e3259)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259533, encodeId=a2d4125953320, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology:WHO引入了HCC新分型？快来看看它长什么样！ , objectType=article, longId=212528, objectId=6bb22125289a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bb22125289a, replyNumber=0, likeNumber=83, createdTime=2021-06-11, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bb22125289a, moduleTitle=Radiology:WHO引入了HCC新分型？快来看看它长什么样！ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bb22125289a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259532, encodeId=e4651259532c5, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用, objectType=article, longId=212482, objectId=d29f212482ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d29f212482ea, replyNumber=0, likeNumber=91, createdTime=2021-06-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d29f212482ea, moduleTitle=Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d29f212482ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259531, encodeId=8db5125953150, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, objectType=article, longId=212415, objectId=b72721241538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b72721241538, replyNumber=0, likeNumber=76, createdTime=2021-06-09, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b72721241538, moduleTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b72721241538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259530, encodeId=cc22125953074, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, objectType=article, longId=211682, objectId=d50921168225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50921168225, replyNumber=0, likeNumber=86, createdTime=2021-05-24, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50921168225, moduleTitle=Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50921168225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259529, encodeId=659812595297f, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, objectType=article, longId=211606, objectId=ff0121160699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0121160699, replyNumber=0, likeNumber=66, createdTime=2021-05-22, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0121160699, moduleTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0121160699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259528, encodeId=f511125952812, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, objectType=article, longId=211561, objectId=4f32211561f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f32211561f9, replyNumber=0, likeNumber=85, createdTime=2021-05-21, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f32211561f9, moduleTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f32211561f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259527, encodeId=df75125952ef4, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, objectType=article, longId=211491, objectId=32e221149157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e221149157, replyNumber=0, likeNumber=78, createdTime=2021-05-20, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e221149157, moduleTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e221149157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259526, encodeId=031b125952633, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！, objectType=article, longId=210866, objectId=2f0121086637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f0121086637, replyNumber=0, likeNumber=100, createdTime=2021-05-07, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f0121086637, moduleTitle=Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f0121086637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259525, encodeId=bf98125952536, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：放射组学在预测早期HCC复发中的应用, objectType=article, longId=210836, objectId=ae51210836aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae51210836aa, replyNumber=0, likeNumber=89, createdTime=2021-05-07, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae51210836aa, moduleTitle=Radiology：放射组学在预测早期HCC复发中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae51210836aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259524, encodeId=6a96125952439, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现, objectType=article, longId=210789, objectId=6ad8210e89ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad8210e89ae, replyNumber=0, likeNumber=109, createdTime=2021-05-05, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad8210e89ae, moduleTitle=Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad8210e89ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259523, encodeId=b8e31259523ef, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要, objectType=article, longId=210100, objectId=8451210100cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8451210100cd, replyNumber=0, likeNumber=74, createdTime=2021-04-19, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8451210100cd, moduleTitle=Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8451210100cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259522, encodeId=59b71259522ae, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”, objectType=article, longId=205226, objectId=9130205226b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9130205226b7, replyNumber=0, likeNumber=80, createdTime=2021-01-04, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9130205226b7, moduleTitle=FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9130205226b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259521, encodeId=4331125952148, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Nat Genet ：BAHCC1蛋白介导基因沉默和癌症发生的机制, objectType=article, longId=202951, objectId=dc73202951dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc73202951dc, replyNumber=0, likeNumber=0, createdTime=2020-11-07, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc73202951dc, moduleTitle=Nat Genet ：BAHCC1蛋白介导基因沉默和癌症发生的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc73202951dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259520, encodeId=d751125952017, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Keytruda联合Lenvima治疗肝细胞癌（HCC）：遭遇滑铁卢, objectType=article, longId=197268, objectId=1caa19e26835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1caa19e26835, replyNumber=0, likeNumber=95, createdTime=2020-07-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1caa19e26835, moduleTitle=Keytruda联合Lenvima治疗肝细胞癌（HCC）：遭遇滑铁卢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1caa19e26835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259519, encodeId=e28312595196d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=NIHCC发布迄今世界很大的CT医学影像数据集DeepLesion（附下载）, objectType=article, longId=195882, objectId=693819588287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693819588287, replyNumber=0, likeNumber=70, createdTime=2020-06-16, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693819588287, moduleTitle=NIHCC发布迄今世界很大的CT医学影像数据集DeepLesion（附下载）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693819588287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259518, encodeId=293912595183d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=ASCO肝细胞癌（HCC）相关口头报告速览, objectType=article, longId=194518, objectId=32961945180c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32961945180c, replyNumber=0, likeNumber=57, createdTime=2020-05-23, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32961945180c, moduleTitle=ASCO肝细胞癌（HCC）相关口头报告速览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32961945180c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259517, encodeId=daba125951e97, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药, objectType=article, longId=193347, objectId=3a3319334ea1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a3319334ea1, replyNumber=0, likeNumber=110, createdTime=2020-05-03, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a3319334ea1, moduleTitle=ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a3319334ea1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果

2021-07-15

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2021-07-03

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology:对于HCC的诊断，不要只看动脉期！

2021-06-16

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology:WHO引入了HCC新分型？快来看看它长什么样！

2021-06-11

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用

2021-06-10

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。

2021-06-09

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Hepatol Int：安罗替尼（Anlotinib）治疗晚期肝细胞癌（HCC）的疗效和安全性：来自ALTER‑0802研究结果

2021-05-24

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估

2021-05-22

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择

2021-05-21

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性

2021-05-20

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：对于HCC患者来说，也许在MRI对比剂选择时就已决定了最终预后！

2021-05-07

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：放射组学在预测早期HCC复发中的应用

2021-05-07

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：结直肠癌肝转移病灶也有HCC相似的MRI表现

2021-05-05

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要

2021-04-19

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”

2021-01-04

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Nat Genet ：BAHCC1蛋白介导基因沉默和癌症发生的机制

2020-11-07

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Keytruda联合Lenvima治疗肝细胞癌（HCC）：遭遇滑铁卢

2020-07-10

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

NIHCC发布迄今世界很大的CT医学影像数据集DeepLesion（附下载）

2020-06-16

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

ASCO肝细胞癌（HCC）相关口头报告速览

2020-05-23

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药

2020-05-03

科室
- - 订阅+
  - 更多科室
工具
服务